EMEA-002522-PIP01-18

Key facts

Active substance
tisotumab vedotin
Therapeutic area
Psychiatry
Decision number
P/0216/2019
PIP number
EMEA-002522-PIP01-18
Pharmaceutical form(s)
Powder for concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of cervical cancer
Route(s) of administration
Intravenous use
Contact for public enquiries
Genmab A/S

Tel.: +45 70202728
E-mail: clinicaltrials@genmab.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating